[Structural changes of cell membrane and cell differentiation induction].
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002454:Cell Differentiation / Q000187:drug effects*; D006801:Humans; D007942:Leukemia, Experimental / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008246:Lysophospholipids; D051379:Mice; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010743:Phospholipids / Q000627:therapeutic use*; D011726:Pyridinium Compounds / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D008246:Lysophospholipids; D009943:Organophosphorus Compounds; D010743:Phospholipids; D011726:Pyridinium Compounds; C046706:2(2-(dodecyloxy)ethoxy)ethyl-2-pyridioethyl phosphate